Results 211 to 220 of about 184,542 (286)

Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data. [PDF]

J Clin Med
Lee YB, Shin BS, Kim M, Suh MK, Youn SW, Lee JY, Kim CW, Lee GY, Kim KH, An J, Kim Y, Kim KJ, Kim DH, Son SW.   +13 more
europepmc   +1 more source

Bra‐Related Chafing in Female Athletes

JEADV Clinical Practice, EarlyView.
Stéphanie Leclerc‐Mercier, Nicolas Kluger   +1 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Research Trends and Insights Regarding MicroRNAs in Psoriasis: A Comprehensive Analysis. [PDF]

Cureus
Örs I, Cosansu NC, Solak B.
europepmc   +1 more source

Unilateral Hyperkeratotic Lesions With a Sporotrichoid Pattern

JEADV Clinical Practice, EarlyView.
José González Fernández, Mariano Ara‐Martín, Francesc Felipo‐Berlanga, Diego Larrosa‐Martínez, Javier Sánchez‐Bernal   +4 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Reduced EZH2 Expression in Circulating CD8-Positive T Cells and Monocytes in Psoriasis. [PDF]

Exp Dermatol
Yamamoto T, Toyoshima R, Li L, Koyama A, Sato S, Shibata S.   +5 more
europepmc   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study. [PDF]

Psoriasis (Auckl)
Gu X, Wang X, Bin Y, Xue R, Zhu G.
europepmc   +1 more source